Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Jul 5, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

sourced metrics

600

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price

+53.3percent_1yr_return

Jun 10, 2026source

Eps

-3.62USD

Apr 30, 2026source

Market Value In Fund

3.6USD

Apr 8, 2026source

Portfolio Weight

4.2percent

Apr 8, 2026source

Discount To Intrinsic Value

40.8percent

Apr 1, 2026source

Ytd Return

11.9percent

Apr 1, 2026source

Free Cash Flow

12.57USD

Apr 1, 2026source

One Year Return

44.6percent

Apr 1, 2026source

Valuation Score

5out_of_6

Apr 1, 2026source

Thirty Day Return

4.3percent

Apr 1, 2026source

One Week Return

-0.9percent

Apr 1, 2026source

Intrinsic Value Per Share

201.05USD

Apr 1, 2026source

Acquisition Charge Per Share

2.35USD

Mar 25, 2026source

Acquisition Charge

5.8USD

Mar 25, 2026source

Analyst Target Price

128.04USD

Mar 1, 2026source

Price To Earnings Ratio

11.85ratio

Feb 23, 2026source

Company Age

130years

Feb 19, 2026source

Active Clinical Trials

1600trials

Jan 7, 2026source

Stated objectives

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source

target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source

stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source

stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source

stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source

stated

Full-year sales forecast

source

target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source

target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Improving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies

source

stated

Become the premier research-intensive biopharmaceutical company in the world

source

stated

Deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals

source

stated

Relationship graph · 600 connections

Developed by

233

Competes with

Employs

Partnered with

acquired by

regulates

Covered by

headquartered in

Via News coverage

Star Bulk Carriers Corp., Brookline Bancorp, Another 7 Companies Have A High Estimated Dividend Yield

September 16, 2024

Redwood Trust And 3 Other Stocks Have Very High Payout Ratio

July 20, 2024

Gilead Sciences And 4 Other Stocks Have Very High Payout Ratio

July 9, 2024

Acadia Realty Trust And 5 Other Stocks Have Very High Payout Ratio

July 5, 2024

Argan And 5 Other Stocks Have Very High Payout Ratio

July 3, 2024

Evercore Partners And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

June 22, 2024

Blackstone Mortgage Trust, Dorchester Minerals, L.P., Another 8 Companies Have A High Estimated Dividend Yield

June 16, 2024

Healthcare Realty Trust Incorporated, Iron Mountain Incorporated, Another 2 Companies Have A High Estimated Dividend Yield

June 13, 2024

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →